Cogent's Chronic Immune Disorder Drug Has Strong Potential To Become A Blockbuster: Analyst
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 08 2025
0mins
Source: Benzinga
Clinical Trial Success: Cogent Biosciences announced that its drug bezuclastinib showed significant clinical benefits for patients with non-advanced systemic mastocytosis, achieving key endpoints in the SUMMIT trial and demonstrating a notable reduction in symptoms compared to placebo.
Market Potential and Future Plans: The company plans to submit a new drug application to the FDA by the end of 2025, with analysts predicting strong market potential for bezuclastinib, estimating the U.S. market for non-advanced systemic mastocytosis to exceed $2 billion.
Analyst Views on SNY
Wall Street analysts forecast SNY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SNY is 63.50 USD with a low forecast of 58.00 USD and a high forecast of 69.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 47.470
Low
58.00
Averages
63.50
High
69.00
Current: 47.470
Low
58.00
Averages
63.50
High
69.00
About SNY
Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
